Literature DB >> 16023594

Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death.

Beth A A Weaver1, Don W Cleveland.   

Abstract

Disrupted passage through mitosis often leads to chromosome missegregation and the production of aneuploid progeny. Aneuploidy has long been recognized as a frequent characteristic of cancer cells and a possible cause of tumorigenesis. Drugs that target mitotic spindle assembly are frequently used to treat various types of human tumors. These lead to chronic mitotic arrest from sustained activation of the mitotic checkpoint. Here, we review the linkage between the mitotic checkpoint, aneuploidy, adaptation from mitotic arrest, and antimitotic drug-induced cell death.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023594     DOI: 10.1016/j.ccr.2005.06.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  199 in total

1.  Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.

Authors:  Takumi Kawabata; Susumu Tanimura; Kohei Asai; Ryohei Kawasaki; Yumi Matsumaru; Michiaki Kohno
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

2.  Depletion of p31comet protein promotes sensitivity to antimitotic drugs.

Authors:  Hoi Tang Ma; Yan Yan Chan; Xiao Chen; Kin Fan On; Randy Y C Poon
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

Review 3.  Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint.

Authors:  P Silva; J Barbosa; A V Nascimento; J Faria; R Reis; H Bousbaa
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

Review 4.  Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy.

Authors:  A Ogden; P C G Rida; R Aneja
Journal:  Cell Death Differ       Date:  2012-06-01       Impact factor: 15.828

5.  An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor.

Authors:  Hiroko Kamei; Robert C Jackson; Daniella Zheleva; Fordyce A Davidson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-08-08       Impact factor: 2.745

6.  Cellular abundance of Mps1 and the role of its carboxyl terminal tail in substrate recruitment.

Authors:  Tingting Sun; Xiaomei Yang; Wei Wang; Xiaojuan Zhang; Quanbin Xu; Songcheng Zhu; Robert Kuchta; Guanjun Chen; Xuedong Liu
Journal:  J Biol Chem       Date:  2010-09-30       Impact factor: 5.157

7.  Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.

Authors:  Uday Bhanu Maachani; Tamalee Kramp; Ryan Hanson; Shuping Zhao; Orieta Celiku; Uma Shankavaram; Riccardo Colombo; Natasha J Caplen; Kevin Camphausen; Anita Tandle
Journal:  Mol Cancer Res       Date:  2015-02-26       Impact factor: 5.852

8.  Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines.

Authors:  Kazuaki Matsuoka; Teiji Takechi
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

9.  Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells.

Authors:  Young Bin Hong; Hyo Jin Kang; Hee Jeong Kim; Eliot M Rosen; Sivanesan Dakshanamurthy; Riccardo Rondanin; Riccardo Baruchello; Giuseppina Grisolia; Simoni Daniele; Insoo Bae
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

10.  Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.

Authors:  Kathryn E Reinicke; Mary J Kuffel; Matthew P Goetz; Matthew M Ames
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-11       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.